50mg Tirzepatide: Separating Fact from a Common Misconception

The myth: that tirzepatide comes in large numbered doses like 50mg

Search for tirzepatide and you'll sometimes find listings quoting doses that bear no relation to the licensed product, 50mg being one of the most common. It's easy to see where the confusion starts. Semaglutide oral tablets for diabetes (Rybelsus) do come in milligram doses that look larger in isolation, and some compounded or illicitly manufactured products use entirely different concentration conventions. None of that applies to the genuine, MHRA-licensed tirzepatide sold in the UK as Mounjaro.

The actual licensed strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg) are the only ones with clinical trial evidence behind them. SURMOUNT-1, the pivotal trial published in the New England Journal of Medicine, tested tirzepatide at 5mg, 10mg and 15mg in over 2,500 adults with obesity and found average body-weight reductions of around 15–21% over 72 weeks. Those numbers were achieved with the licensed doses. There is no 50mg data, because there is no 50mg product.

Seeing a product labelled tirzepatide 50mg should immediately prompt scepticism. The MHRA Drug Safety Updates index documents the regulator's escalating action against counterfeit and illicitly produced weight-loss pens in the UK. Fake pens have in some cases contained insulin rather than the labelled medicine, a potentially life-threatening substitution. The safe route is always a prescription from a registered prescriber, dispensed by a pharmacy you can verify on the GPhC register.

Why tirzepatide doses are this small, and what makes them effective

Milligrams matter differently in different drug classes. Tirzepatide is a dual GIP and GLP-1 receptor agonist: it acts on two gut-hormone receptors involved in appetite regulation and blood sugar control, and it does so with measurable biological effect at microgram-to-milligram quantities. The licensed range reflects careful dose-finding work across the SURMOUNT programme, which involved thousands of adults across multiple trials. A 15mg weekly dose is already the top of that carefully studied range.

The starting dose of 2.5mg exists not because it's therapeutic at that level, but because stepping in gently reduces the likelihood of nausea and other gastrointestinal symptoms in the early weeks. From there, a prescriber typically moves the dose upward through the 5mg, 7.5mg, and higher strengths at roughly four-week intervals, watching how each step is tolerated. If you are on one of the mid-range steps, our tirzepatide 30mg page explains what that supply format covers and how it fits into the dosing schedule. The ceiling of 15mg is where the strongest efficacy data sits, and it's a ceiling set by the evidence, not an arbitrary limit. You can read more about how the full treatment works on our tirzepatide overview.

Contrast this with how a counterfeit product might be labelled. Someone producing fake pens without pharmaceutical oversight has no reason to adhere to the licensed schedule. A "50mg" figure might reflect a different active ingredient, a wildly different concentration, or simply a number invented to suggest potency. None of those scenarios is safe.

Who is actually eligible for tirzepatide in the UK, the licensed criteria

Eligibility for the genuine, licensed medicine depends on clinical assessment rather than a self-selected dose. The UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as hypertension, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't determine suitability, a prescriber looks at the full picture, including other medicines, health history and any contraindications.

NICE's appraisal of tirzepatide, TA1026, sets out recommendations for NHS use at BMI 35 and above alongside at least one weight-related comorbidity. Private treatment through a regulated online pharmacy follows the licensed eligibility criteria from the medicine's SmPC, which is slightly broader. Our Mounjaro page covers the full eligibility picture in detail, including how NHS and private criteria differ.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a history of medullary thyroid carcinoma or MEN2 should not take it; a history of pancreatitis also requires careful prescriber discussion before starting.

What genuinely licensed tirzepatide looks like when it arrives

If you receive a prescription for Mounjaro through a GPhC-registered pharmacy, what actually turns up is a Eli Lilly KwikPen, sealed in its original manufacturer's packaging, inside a plain unbranded box, nothing on the outside indicates what's inside. Each pen holds four weekly doses. You'll get a DPD tracking notification before it arrives, so there's no guessing. The pen goes straight in the fridge door. The patient information leaflet inside explains storage, injection technique and what to do if you miss a dose.

That specificity matters. Counterfeit or grey-market products often lack the cold-chain handling genuine pens require, arrive without proper labelling, and carry none of the post-market safety monitoring that applies to medicines in the licensed supply chain. If you are considering a higher-strength pen, our tirzepatide 60mg page details what that supply format contains and which stage of treatment it is intended for, while our tirzepatide l page covers the larger pen option and how it compares. If you're weighing up options, the cost comparison between providers is genuinely secondary to knowing the supply chain is legitimate. Our Mounjaro price comparison guide explains what a typical private prescription price includes and what it doesn't. For a broader look at weight-loss treatment options, our treatment overview sets out the full picture.

Questions about your specific situation (current medications, health history, which dose might be right for you) are exactly what the consultation process is for. A prescriber, not an algorithm, reads your answers. If tirzepatide is clinically suitable for you, a prescription follows. If you'd like to get started, you can begin your free consultation at any time.